Stryker Corporation vs Vale SA — how do they compare? Stryker Corporation trades at $277.33 (market cap $106.24B), while Vale SA trades at $13.62 (market cap $57.32B). The key difference: Stryker Corporation is the larger of the two by market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and Vale SA for 109 Days on average.
| SYK | VALE | |
|---|---|---|
Market Cap | $106.24B | $57.32B |
Volume | 2,982,001 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $388.35 | $17.82 |
52-Week Low | $269.75 | $10.75 |
Typical Hold Time | 21 Days | 109 Days |
Enterprise Value | $117.70B | $73.56B |
Dividend Yield | 1.27% | 8.87% |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
VALE trades at $13.62, near recent lows, with a bearish technical outlook and mixed sentiment. The stock has missed earnings expectations in recent quarters, with Q3 2026 EPS expected at $0.4212. Revenue has declined from $43.8B in 2022 to $38.4B in 2025, though 2026 is projected at $41.2B. Net income margin compressed to 5.11% in 2025. Analyst consensus is a 'Hold' with a $16.21 price target, indicating modest upside potential from current levels.
VALE faces headwinds from cyclical commodity exposure and cost inflation, but its base metals segment shows growth. Investment appeal hinges on iron ore price stability and execution on cost controls. Risks include regulatory challenges in Brazil and volatile raw material markets. The stock offers a dividend yield but requires careful monitoring of earnings trajectory and macroeconomic factors affecting mining sectors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →